Outcomes of high-risk acute promyelocytic leukemia patients treated with arsenic trioxide (ATO)/all trans retinoic acid (ATRA) based induction and consolidation without maintenance phase: A case Series | Zendy

Gaurav Shah | Zendy; Fady M. Mikhail | Zendy; Kimo Bachiasvili | Zendy; Pankit Vachhani | Zendy; Harry P. Erba | Zendy; Nikolaos Papadantonakis | Zendy

Open Access

Outcomes of high-risk acute promyelocytic leukemia patients treated with arsenic trioxide (ATO)/all trans retinoic acid (ATRA) based induction and consolidation without maintenance phase: A case Series

Author(s) -

Gaurav Shah,

Fady M. Mikhail,

Kimo Bachiasvili,

Pankit Vachhani,

Harry P. Erba,

Nikolaos Papadantonakis

Publication year - 2019

Publication title -

hematology/oncology and stem cell therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.666

H-Index - 22

eISSN - 1658-3876

pISSN - 2589-0646

DOI - 10.1016/j.hemonc.2019.08.006

Subject(s) - arsenic trioxide , acute promyelocytic leukemia , retinoic acid , medicine , maintenance therapy , tretinoin , leukemia , oncology , gastroenterology , arsenic , chemotherapy , chemistry , biochemistry , organic chemistry , gene

Patients with high-risk acute promyelocytic leukemia (APL) have inferior outcomes compared with patients with low-risk APL, predominantly due to higher risk of early mortality related to hemorrhage. The majority of regimens contain prolonged maintenance, but the impact of this phase is not clear in the era of all trans retinoic acid (ATRA) and arsenic trioxide (ATO). We present a retrospective analysis of 10 patients that were treated for high risk APL based on the consolidation treatment phase of APL 0406 study without subsequent maintenance. With a median follow up of 38 months, all patients remain in remission.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research